BALPHARMANSEBal Pharma Limited· PharmaceuticalsMinimalNeutral
Announced Fri, 17 Apr · 15:15 IST

Shailesh Siroya has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

BALPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.9%1-day move
₹77.00
prior close
₹78.72
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0-1.8+1.9+0.3+0.3+1.3-1.3-1.1+13.0+0.5+13.4+12.9
Up moveDown movePending
AI summary

Shailesh Siroya, a promoter/substantial shareholder of Bal Pharma Limited, has submitted a declaration to the exchanges confirming that he has not created any encumbrance (pledge or charge) on his shareholding in the company during the financial year ended 31 March 2026. This filing is a routine compliance requirement under SEBI regulations for promoters to disclose their pledge status periodically. The declaration covers both direct and indirect shareholding.

Likely market impact

A no-encumbrance declaration is generally viewed positively by investors as it indicates the promoter has not leveraged their shares for loans, reducing risk for minority shareholders. No immediate impact on stock price expected from this routine disclosure.